Tokenized Access to Synchron Pre-IPO Equity.

Synchron is building a brain-computer interface (BCI) platform designed to be implanted via blood vessels (non-surgical approach), aiming to make neural control more scalable for patients with severe motor impairment. In November 2025, Synchron announced a $200M Series D to advance commercialization of its Stentrode™ BCI. On the strategic side, multiple outlets reported Apple is working with Synchron around BCI device-control pathways, an unusually strong validation signal from a top-tier consumer platform owner for an emerging modality. If BCIs move from clinical novelty to a developer ecosystem, distribution and standards matter as much as hardware. Investors get exposure to neurotech commercialization plus potential platform-level integration dynamics.